These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 39110357)

  • 1. Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.
    Yoshida K; Nagasaka N; Kondo T; Kobari Y; Ishihara H; Fukuda H; Iizuka J; Ishida H; Takagi T
    Int J Clin Oncol; 2024 Oct; 29(10):1538-1547. PubMed ID: 39110357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
    Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of enhanced multiparameteric MRI diagnostic model for preoperatively predicting surgical methods of inferior vena cava in patients with renal tumors and inferior vena cava tumor thrombus.
    Pei X; Lu M; Liu Z; Liu B; Deng Y; Yuan H; Ma L
    BMC Med Imaging; 2023 Jun; 23(1):86. PubMed ID: 37355601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi.
    Yoshida K; Hata K; Iizuka J; Kondo T; Ishihara H; Ishida H; Nagashima Y; Tanabe K; Takagi T
    In Vivo; 2022; 36(2):1030-1034. PubMed ID: 35241567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative systemic inflammation response index indicates poor prognosis in patients treated with resection of renal cell carcinoma with inferior vena cava tumor thrombus.
    Lv Z; Feng HY; Wang T; Ma X; Zhang X
    Urol Oncol; 2022 Apr; 40(4):167.e9-167.e19. PubMed ID: 35042663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors.
    Xu X; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Cell Oncol (Dordr); 2024 Oct; 47(5):1943-1956. PubMed ID: 39222176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
    Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
    Target Oncol; 2023 Jan; 18(1):159-168. PubMed ID: 36571708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of various imaging in the diagnosis of renal cell carcinoma with inferior vena cava tumor thrombus combined with bland thrombus].
    Li LW; Liu Z; Wang GL; Zhang H; Chen W; Ma J; Zhang L; He W; Ma LL; Wang SM
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):678-683. PubMed ID: 31420621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robot Assisted Laparoscopy Combined with Thoracoscopy in the Treatment of Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus.
    Song C; Chen M; Zhu Z; Chen J; Jin R; Zhang Y; Gong L; Yang Z; Liang X
    Ann Surg Oncol; 2023 Sep; 30(9):5447-5449. PubMed ID: 37285097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety.
    Yanagisawa T; Mori K; Kawada T; Katayama S; Uchimoto T; Tsujino T; Nishimura K; Adachi T; Toyoda S; Nukaya T; Fukuokaya W; Urabe F; Murakami M; Yamanoi T; Bekku K; Komura K; Takahara K; Hashimoto T; Fujita K; Azuma H; Ohno Y; Shiroki R; Uemura H; Araki M; Kimura T;
    Urol Oncol; 2024 Nov; 42(11):374.e21-374.e29. PubMed ID: 39085019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
    Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
    Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.
    Oka S; Inoshita N; Miura Y; Oki R; Miyama Y; Nagamoto S; Ogawa K; Sakaguchi K; Kondoh C; Kurosawa K; Urakami S; Takano T; Okaneya T
    Urol Oncol; 2018 Aug; 36(8):365.e9-365.e14. PubMed ID: 29853346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
    Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
    Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma.
    Ishihara H; Nishimura K; Ikeda T; Fukuda H; Yoshida K; Iizuka J; Kondo T; Takagi T
    Urol Oncol; 2024 Sep; 42(9):291.e27-291.e37. PubMed ID: 38653590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the combination therapy of transcatheter arterial chemoembolization and ablation for hepatocellular carcinoma with inferior vena cava tumor thrombus: A consecutive case series.
    Liu B; Li W; Zheng J
    J Cancer Res Ther; 2020 Sep; 16(5):1186-1190. PubMed ID: 33004769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
    Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
    Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
    Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
    Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.
    Cost NG; Delacroix SE; Sleeper JP; Smith PJ; Youssef RF; Chapin BF; Karam JA; Culp S; Abel EJ; Brugarolas J; Raj GV; Sagalowsky AI; Wood CG; Margulis V
    Eur Urol; 2011 Jun; 59(6):912-8. PubMed ID: 21367518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma.
    Yoshino M; Ishihara H; Nemoto Y; Mizoguchi S; Ikeda T; Nakayama T; Fukuda H; Yoshida K; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
    Target Oncol; 2024 Jul; 19(4):623-633. PubMed ID: 38819770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.